Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for eczema sufferers: experimental drug GHZ339 enters Mid-Stage trial

NCT ID NCT06947993

Symptom relief Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 20, 2026 · Updated 2 times

Summary

This Phase 2 trial is testing an experimental drug called GHZ339 in 224 adults with moderate to severe atopic dermatitis (eczema). Participants will receive either the drug or a placebo, and researchers will measure changes in eczema severity using the EASI score at 16 weeks. The goal is to see if GHZ339 can safely reduce skin inflammation and improve symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GHZ339
What this could lead to
If successful, this could lead to a new treatment option that reduces eczema severity and improves quality of life for people with moderate to severe atopic dermatitis.
What could go wrong
This is an early Phase 2 trial with a small number of participants, so results may not confirm effectiveness. The drug may cause side effects or fail to outperform placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 224 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria of the master protocol: * Able and willing to sign the informed consent (IC) * Patients with a diagnosis of AD and onset of disease for at least 1 year * Moderate to severe AD Key Exclusion Criteria of the master protocol: * Participants with a clinically significant medical condition or infectious disease (specified in sub-protocol) * Participants with clinically significant abnormal hematology, clinical chemistry, or urine test results or clinically significant abnormal ECG * Participant with any other active inflammatory skin disease * Participants with any chronic, uncontrolled medical condition, which would put the participant at increased risk during the study (e.g., uncontrolled: diabetes, hypertension) * Participants with any clinically unstable disease states that would likely require systemic corticosteroids (e.g., uncontrolled asthma) Additional inclusion and exclusion criteria may apply depending on the intervention specific requirements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema dermatitis Eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    70 sites in 15 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Birmingham, Alabama, 35233, United States

  • Novartis Investigative Site

    RECRUITING

    Birmingham, Alabama, 35244, United States

  • Novartis Investigative Site

    RECRUITING

    Fort Smith, Arkansas, 72916, United States

  • Novartis Investigative Site

    RECRUITING

    Fountain Valley, California, 92708, United States

  • Novartis Investigative Site

    RECRUITING

    Los Angeles, California, 90056, United States

  • Novartis Investigative Site

    RECRUITING

    Sacramento, California, 95815, United States

  • Novartis Investigative Site

    RECRUITING

    Santa Ana, California, 92701, United States

  • Novartis Investigative Site

    RECRUITING

    Santa Monica, California, 90404, United States

  • Novartis Investigative Site

    RECRUITING

    Washington D.C., District of Columbia, 20060, United States

  • Novartis Investigative Site

    RECRUITING

    Miami, Florida, 33144, United States

  • Novartis Investigative Site

    RECRUITING

    St. Petersburg, Florida, 33705, United States

  • Novartis Investigative Site

    RECRUITING

    Atlanta, Georgia, 30342, United States

  • Novartis Investigative Site

    RECRUITING

    Macon, Georgia, 31217, United States

  • Novartis Investigative Site

    RECRUITING

    Louisville, Kentucky, 40241, United States

  • Novartis Investigative Site

    RECRUITING

    Brighton, Massachusetts, 02135, United States

  • Novartis Investigative Site

    RECRUITING

    Troy, Michigan, 48084, United States

  • Novartis Investigative Site

    RECRUITING

    Saint Joseph, Missouri, 64506, United States

  • Novartis Investigative Site

    RECRUITING

    Portsmouth, New Hampshire, 03801, United States

  • Novartis Investigative Site

    RECRUITING

    Brooklyn, New York, 11203, United States

  • Novartis Investigative Site

    RECRUITING

    Arlington, Texas, 76011, United States

  • Novartis Investigative Site

    RECRUITING

    Cypress, Texas, 77433, United States

  • Novartis Investigative Site

    RECRUITING

    Dallas, Texas, 75235-9069, United States

  • Novartis Investigative Site

    RECRUITING

    Houston, Texas, 77030, United States

  • Novartis Investigative Site

    RECRUITING

    San Antonio, Texas, 78218, United States

  • Novartis Investigative Site

    RECRUITING

    Caba, Buenos Aires, C1119ACN, Argentina

  • Novartis Investigative Site

    RECRUITING

    Caba, Buenos Aires, C1121ABE, Argentina

  • Novartis Investigative Site

    RECRUITING

    Rosario, Santa Fe Province, S2000DBS, Argentina

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Edmonton, Alberta, T5K 1X3, Canada

  • Novartis Investigative Site

    RECRUITING

    Hamilton, Ontario, L8L 3C3, Canada

  • Novartis Investigative Site

    RECRUITING

    Markham, Ontario, L3P 1X3, Canada

  • Novartis Investigative Site

    RECRUITING

    Montreal, Quebec, H1Y 3L1, Canada

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Verdun, Quebec, H4G 3E7, Canada

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Guangzhou, Guangdong, 510091, China

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Shantou, Guangdong, 515000, China

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Changsha, Hunan, 410008, China

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Changchun, Jilin, 130021, China

  • Novartis Investigative Site

    RECRUITING

    Hangzhou, Zhejiang, 310001, China

  • Novartis Investigative Site

    WITHDRAWN

    Beijing, 100029, China

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Beijing, 100050, China

  • Novartis Investigative Site

    RECRUITING

    Shanghai, 200040, China

  • Novartis Investigative Site

    RECRUITING

    Plzen Bory, 301 00, Czechia

  • Novartis Investigative Site

    RECRUITING

    Prague, 100 34, Czechia

  • Novartis Investigative Site

    RECRUITING

    Prague, 130 00, Czechia

  • Novartis Investigative Site

    RECRUITING

    Prague, 150 06, Czechia

  • Novartis Investigative Site

    RECRUITING

    Prague, 180 81, Czechia

  • Novartis Investigative Site

    RECRUITING

    Brest, 29609, France

  • Novartis Investigative Site

    RECRUITING

    Lille, 59037, France

  • Novartis Investigative Site

    RECRUITING

    Lorient, 56322, France

  • Novartis Investigative Site

    RECRUITING

    Paris, 75475, France

  • Novartis Investigative Site

    RECRUITING

    Pierre-Bénite, 69495, France

  • Novartis Investigative Site

    RECRUITING

    Reims, 51100, France

  • Novartis Investigative Site

    RECRUITING

    Rouen, 76031, France

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Frankfurt am Main, Hesse, 60590, Germany

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Mainz, Rhineland-Palatinate, 55128, Germany

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Bad Bentheim, 48455, Germany

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Dresden, 01097, Germany

  • Novartis Investigative Site

    RECRUITING

    Hamburg, 20246, Germany

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Heidelberg, 69120, Germany

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Magdeburg, 39120, Germany

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Münster, 48149, Germany

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Oldenburg, 26133, Germany

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Pécs, Baranya, 7623, Hungary

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Debrecen, Hajdu Bihar Megye, 4032, Hungary

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Budapest, 1033, Hungary

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Budapest, 1083, Hungary

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Szeged, 6725, Hungary

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Ancona, AN, 60020, Italy

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Cona, FE, 44124, Italy

  • Novartis Investigative Site

    RECRUITING

    Pisa, PI, 56126, Italy

  • Novartis Investigative Site

    RECRUITING

    Nagoya, Aichi-ken, 4678602, Japan

  • Novartis Investigative Site

    RECRUITING

    Matsudo, Chiba, 2710092, Japan

  • Novartis Investigative Site

    RECRUITING

    Kawasaki, Kanagawa, 211-0063, Japan

  • Novartis Investigative Site

    RECRUITING

    Yokohama, Kanagawa, 220-6208, Japan

  • Novartis Investigative Site

    RECRUITING

    Habikino, Osaka, 5838588, Japan

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Shinagawa Ku, Tokyo, 1418625, Japan

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Fukuoka, 8128582, Japan

  • Novartis Investigative Site

    RECRUITING

    Kyoto, 6078062, Japan

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Rotterdam, South Holland, 3015 GD, Netherlands

  • Novartis Investigative Site

    RECRUITING

    Utrecht, 3584 CX, Netherlands

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Warsaw, Masovian Voivodeship, 02-953, Poland

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Katowice, 40-611, Poland

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Lodz, 90-436, Poland

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Lublin, 20-573, Poland

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Warsaw, 02-962, Poland

  • Novartis Investigative Site

    WITHDRAWN

    Bardejov, 085 01, Slovakia

  • Novartis Investigative Site

    RECRUITING

    Komárno, 945 01, Slovakia

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Košice, 040 22, Slovakia

  • Novartis Investigative Site

    RECRUITING

    Košice, 041 90, Slovakia

  • Novartis Investigative Site

    RECRUITING

    Prešov, 080 01, Slovakia

  • Novartis Investigative Site

    RECRUITING

    Ansan, Gyeonggi-do, 425-801, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 03722, South Korea

  • Novartis Investigative Site

    RECRUITING

    Badalona, Barcelona, 08916, Spain

  • Novartis Investigative Site

    RECRUITING

    Alicante, 03010, Spain

  • Novartis Investigative Site

    RECRUITING

    Granada, 18016, Spain

  • Novartis Investigative Site

    RECRUITING

    Las Palmas GC, 35010, Spain

  • Novartis Investigative Site

    RECRUITING

    Madrid, 28006, Spain

  • Novartis Investigative Site

    RECRUITING

    Madrid, 28041, Spain

  • Novartis Investigative Site

    RECRUITING

    Pontevedra, 36003, Spain

  • Novartis Investigative Site

    RECRUITING

    Kaohsiung City, 833, Taiwan

  • Novartis Investigative Site

    RECRUITING

    Taipei, 10002, Taiwan

  • Novartis Investigative Site

    RECRUITING

    Taipei, 11217, Taiwan

  • Novartis Investigative Site

    RECRUITING

    Taipei, 11490, Taiwan

  • Novartis Investigative Site

    SUSPENDED

    Dudley, West Midlands, DY1 2HQ, United Kingdom

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Liverpool, L7 8XP, United Kingdom

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    London, SE1 9RT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.